Poseida Therapeutics, Inc. – Response to Investor InquiryMerger Agreement • November 26th, 2024 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances)
On November 25, 2024, the Company, Roche Holdings, Inc., a Delaware corporation (“Parent” or “Roche”) and Blue Giant Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Roche (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which Merger Sub will commence a tender offer (the “Tender Offer”) no later than December 10, 2024, to acquire all issued and outstanding shares of the Company’s common stock at an offer price of $9.00 per share in cash (the “Cash Amount”), plus one non-tradeable contingent value right (each, a “CVR”) per share, with each CVR representing the right to receive certain contingent cash payments of up to an aggregate amount of $4.00 per share upon the achievement of specified milestones (collectively, the “Tender Offer Consideration”). If successful, the Tender Offer will be followed by a merger of Merger Sub with and into the Company (the “Merger”), with the Company continuing as the surviving cor
